Welcome to our dedicated page for Protalix BioTherapeutics SEC filings (Ticker: PLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Protalix BioTherapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Protalix BioTherapeutics's regulatory disclosures and financial reporting.
Protalix BioTherapeutics (NYSE:PLX) filed an 8-K disclosing the results of its 2025 Annual Meeting held on June 26, 2025.
- Eight directors elected: top nominee received 22.4 M votes for versus 1.9 M withheld; 12.7 M broker non-votes across the slate.
- Say-on-pay approved: 16.4 M for, 7.5 M against, 0.38 M abstentions, 12.7 M broker non-votes.
- PwC Israel ratified as auditor for FY 2025: 34.9 M for, 1.6 M against, 0.46 M abstentions.
No additional material actions or strategic updates were reported.